Cholic acidCAS# 81-25-4 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 81-25-4 | SDF | Download SDF |
| PubChem ID | 221493 | Appearance | White powder |
| Formula | C24H40O5 | M.Wt | 408.6 |
| Type of Compound | Steroids | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 50 mg/mL (122.38 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | (4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid | ||
| SMILES | CC(CCC(=O)O)C1CCC2C1(C(CC3C2C(CC4C3(CCC(C4)O)C)O)O)C | ||
| Standard InChIKey | BHQCQFFYRZLCQQ-OELDTZBJSA-N | ||
| Standard InChI | InChI=1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13-,14+,15-,16-,17+,18+,19-,20+,22+,23+,24-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. It prevents hepatic TG accumulation, VLDL secretion, and elevated serum TG in mouse models of hypertriglyceridemia;at the molecular level, CA decreases hepatic expression of SREBP-1c and its lipogenic target genes. |
| Targets | cAMP | Sodium Channel | SREBP-1c |
| In vitro | Design of β-CD-surfactant complex-coated liquid crystal droplets for the detection of cholic acid via competitive host-guest recognition.[Pubmed: 25892566]Chem Commun (Camb). 2015 Apr 20.β-CD-C14TAB complex-coated 5CB droplets are designed by the adsorption of β-CD-C14TAB complexes at the 5CB/aqueous interface. We show that the 5CB droplets can be used as an optical probe for the selective detection of Cholic acid in aqueous solution containing uric acid and urea via competitive host-guest recognition. |
| In vivo | Cholic acid induces a Cftr dependent biliary secretion and liver growth response in mice.[Pubmed: 25680200]PLoS One. 2015 Feb 13;10(2):e0117599.The cause of Cystic fibrosis liver disease (CFLD), is unknown. It is well recognized that hepatic exposure to hydrophobic bile salts is associated with the development of liver disease. For this reason, we hypothesize that, CFTR dependent variations, in the hepatic handling of hydrophobic bile salts, are related to the development CFLD.
|
| Cell Research | Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c.[Pubmed: 15146238 ]J Clin Invest. 2004 May;113(10):1408-18.
|
| Animal Research | Diet supplementation with cholic acid promotes intestinal epithelial proliferation in rats exposed to γ-radiation.[Pubmed: 25455456]Toxicol Lett. 2014 Oct 17;232(1):246-252.Consumption of a high-fat diet increases some secondary bile acids (BAs) such as deoxyCholic acid (DCA) in feces. DCA is derived from Cholic acid (CA), a primary BA.
|
Cholic acid Dilution Calculator
Cholic acid Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4474 mL | 12.2369 mL | 24.4738 mL | 48.9476 mL | 61.1845 mL |
| 5 mM | 0.4895 mL | 2.4474 mL | 4.8948 mL | 9.7895 mL | 12.2369 mL |
| 10 mM | 0.2447 mL | 1.2237 mL | 2.4474 mL | 4.8948 mL | 6.1185 mL |
| 50 mM | 0.0489 mL | 0.2447 mL | 0.4895 mL | 0.979 mL | 1.2237 mL |
| 100 mM | 0.0245 mL | 0.1224 mL | 0.2447 mL | 0.4895 mL | 0.6118 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.
In Vitro:Cholic acid competitively binds Na+/taurocholate cotransporting polypeptide (NTCP) on HepG2 cells and significantly inhibits the uptake of Cholic acid (CA)-nanoliposomes (LPs)-Doxorubicin (DOX)-HCl, which indicates that CA-LPs-DOX-HCl are also uptaken via NTCP-mediated endocytosis pathway[1].
In Vivo:Cholic acid feeding leads to increased CYP2D6 expression in CYP2D6-humanized mice. As a cholestasis model, Tg-CYP2D6 mice are fed a Cholic acid (CA)-supplemented diet for over 1 week. The treatment is known to increase bile acid pool size by 2-fold and to replace ~90% of bile acids with CA, recapitulating the features of cholestatic conditions in humans[2].
References:
[1]. Li Y, et al. Mechanism of hepatic targeting via oral administration of DSPE-PEG-Cholic acid-modified nanoliposomes. Int J Nanomedicine. 2017 Feb 28;12:1673-1684.
[2]. Pan X, et al. Cholic acid Feeding Leads to Increased CYP2D6 Expression in CYP2D6-Humanized Mice. Drug Metab Dispos. 2017 Apr;45(4):346-352.
- Taurocholic acid
Catalog No.:BCN6954
CAS No.:81-24-3
- 2-Amino-1-naphthalenesulfonic acid
Catalog No.:BCC8519
CAS No.:81-16-3
- Musk ketone
Catalog No.:BCN8357
CAS No.:81-14-1
- 6-Amino-1-naphthalenesulfonic acid
Catalog No.:BCC8758
CAS No.:81-05-0
- 20R-Ginsenoside Rg2
Catalog No.:BCN2554
CAS No.:80952-72-3
- (20R)-Ginsenoside Rh1
Catalog No.:BCN3700
CAS No.:80952-71-2
- Zingibroside R1
Catalog No.:BCN3433
CAS No.:80930-74-1
- Gnetumontanin B
Catalog No.:BCN3756
CAS No.:809237-87-4
- Concanamycin A
Catalog No.:BCC3919
CAS No.:80890-47-7
- 3,22-Dihydroxyolean-12-en-29-oic acid
Catalog No.:BCN1347
CAS No.:808769-54-2
- Pyracrenic acid
Catalog No.:BCN7455
CAS No.:80832-44-6
- FG-4592 (ASP1517)
Catalog No.:BCC2227
CAS No.:808118-40-3
- Sennoside A
Catalog No.:BCN1002
CAS No.:81-27-6
- Purpurin
Catalog No.:BCN3477
CAS No.:81-54-9
- Warfarin
Catalog No.:BCC5221
CAS No.:81-81-2
- Rhodamine B
Catalog No.:BCN7215
CAS No.:81-88-9
- 4-Hydroxy-4-(methoxycarbonylmethyl)cyclohexanone
Catalog No.:BCN1346
CAS No.:81053-14-7
- Methyl 4-prenyloxycinnamate
Catalog No.:BCN7520
CAS No.:81053-49-8
- EUK 134
Catalog No.:BCC4317
CAS No.:81065-76-1
- Kauniolide
Catalog No.:BCC5313
CAS No.:81066-45-7
- Pravastatin
Catalog No.:BCC4141
CAS No.:81093-37-0
- Cisapride
Catalog No.:BCC4207
CAS No.:81098-60-4
- Clarithromycin
Catalog No.:BCC9219
CAS No.:81103-11-9
- Racecadotril
Catalog No.:BCC4614
CAS No.:81110-73-8
Diet supplementation with cholic acid promotes intestinal epithelial proliferation in rats exposed to gamma-radiation.[Pubmed:25455456]
Toxicol Lett. 2015 Jan 5;232(1):246-52.
Consumption of a high-fat diet increases some secondary bile acids (BAs) such as deoxyCholic acid (DCA) in feces. DCA is derived from Cholic acid (CA), a primary BA. We evaluated intestinal epithelial proliferation and BA metabolism in response to oral administration of Cholic acid (CA) in rats to determine the influence of a CA diet on the responses of gut epithelia to gamma-rays. WKAH/HkmSlc rats were divided into two dietary groups: control diet or CA-supplemented (2g/kg diet) diet. Some of the rats from each group were irradiated with gamma-rays, and epithelial cell proliferation in the colon was analyzed histochemically. Unirradiated CA-fed rats had high levels of DCA and CA in the sera, as well as the presence of tauroCholic acid in their feces. Significant increases were observed in both epithelial proliferation and the number of epithelial cells in the colon of the CA-fed rats, and this effect was observed at 8 weeks after gamma-ray exposure. Furthermore, extracts from both cecal contents and sera of the unirradiated CA-fed rats promoted proliferation of IEC-6 cells. These results indicate that BAs in enterohepatic circulation promote proliferation and survival of the intestinal epithelium after receiving DNA damage.
Cholic acid induces a Cftr dependent biliary secretion and liver growth response in mice.[Pubmed:25680200]
PLoS One. 2015 Feb 13;10(2):e0117599.
The cause of Cystic fibrosis liver disease (CFLD), is unknown. It is well recognized that hepatic exposure to hydrophobic bile salts is associated with the development of liver disease. For this reason, we hypothesize that, CFTR dependent variations, in the hepatic handling of hydrophobic bile salts, are related to the development CFLD. To test our hypothesis we studied, in Cftr-/- and control mice, bile production, bile composition and liver pathology, in normal feeding condition and during cholate exposure, either acute (intravenous) or chronic (three weeks via the diet). In Cftr-/- and control mice the basal bile production was comparable. Intravenous taurocholate increased bile production to the same extent in Cftr-/- and control mice. However, chronic cholate exposure increased the bile flow significantly less in Cftr-/- mice than in controls, together with significantly higher biliary bile salt concentration in Cftr-/- mice. Prolonged cholate exposure, however, did not induce CFLD like pathology in Cftr-/- mice. Chronic cholate exposure did induce a significant increase in liver mass in controls that was absent in Cftr-/- mice. Chronic cholate administration induces a cystic fibrosis-specific hepatobiliary phenotype, including changes in bile composition. These changes could not be associated with CFLD like pathological changes in CF mouse livers. However, chronic cholate administration induces liver growth in controls that is absent in Cftr-/- mice. Our findings point to an impaired adaptive homeotrophic liver response to prolonged hydrophobic bile salt exposure in CF conditions.
Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c.[Pubmed:15146238]
J Clin Invest. 2004 May;113(10):1408-18.
We explored the effects of bile acids on triglyceride (TG) homeostasis using a combination of molecular, cellular, and animal models. Cholic acid (CA) prevents hepatic TG accumulation, VLDL secretion, and elevated serum TG in mouse models of hypertriglyceridemia. At the molecular level, CA decreases hepatic expression of SREBP-1c and its lipogenic target genes. Through the use of mouse mutants for the short heterodimer partner (SHP) and liver X receptor (LXR) alpha and beta, we demonstrate the critical dependence of the reduction of SREBP-1c expression by either natural or synthetic farnesoid X receptor (FXR) agonists on both SHP and LXR alpha and LXR beta. These results suggest that strategies aimed at increasing FXR activity and the repressive effects of SHP should be explored to correct hypertriglyceridemia.
Design of beta-CD-surfactant complex-coated liquid crystal droplets for the detection of cholic acid via competitive host-guest recognition.[Pubmed:25892566]
Chem Commun (Camb). 2015 May 28;51(43):8912-5.
beta-CD-C14TAB complex-coated 5CB droplets are designed by the adsorption of beta-CD-C14TAB complexes at the 5CB/aqueous interface. We show that the 5CB droplets can be used as an optical probe for the selective detection of Cholic acid in aqueous solution containing uric acid and urea via competitive host-guest recognition.
Hydrophilic modification of PVDF microfiltration membranes by adsorption of facial amphiphile cholic acid.[Pubmed:25454658]
Colloids Surf B Biointerfaces. 2014 Nov 1;123:809-13.
Amphiphilic molecules have been widely used in surface modification of polymeric materials. Bile acids are natural biological compounds and possess special facial amphiphilic structure with a unusual distribution of hydrophobic and hydrophilic regions. Based on the facial amphiphilicity, Cholic acid (CA), one of the bile acids, was utilized for the hydrophilic modification of poly(vinylidene fluoride) (PVDF) microfiltration membranes via the hydrophobic interactions between the hydrophobic face of CA and the membrane surfaces. Ethanol, methanol, and water were respectively used as solvent during CA adsorption procedure. Their polarity affects the CA adsorption amount, as similar to CA concentration and adsorption time. There are no changes on the membrane surface morphology after CA adsorption. The hydrophilicity of PVDF membranes is greatly enhanced and the water drops permeates into the CA modified membranes quickly after modification. All these factors benefit to the permeation flux of membrane for water. When CA concentration is higher than 0.088 M, the water permeation flux is doubled as compared with the nascent PVDF membrane and shows a good stability during filtration procedure. These results reveal the promising potential of facial amphiphilic bile acids for the surface modification of polymeric materials.
